Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $8.65, but opened at $9.00. Kodiak Sciences shares last traded at $9.55, with a volume of 299,816 shares traded.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on KOD shares. Jefferies Financial Group upgraded Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 target price on the stock in a research note on Monday, December 9th. HC Wainwright restated a "neutral" rating and issued a $3.00 target price on shares of Kodiak Sciences in a research report on Friday, November 15th. Finally, Barclays lifted their price target on Kodiak Sciences from $3.00 to $4.00 and gave the company an "underweight" rating in a report on Friday, November 15th.
View Our Latest Stock Report on Kodiak Sciences
Kodiak Sciences Trading Up 6.9 %
The stock has a 50-day simple moving average of $5.81 and a 200 day simple moving average of $3.77. The stock has a market capitalization of $486.77 million, a price-to-earnings ratio of -2.53 and a beta of 2.38.
Hedge Funds Weigh In On Kodiak Sciences
Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in Kodiak Sciences during the third quarter valued at approximately $33,000. Meeder Asset Management Inc. acquired a new stake in shares of Kodiak Sciences in the 2nd quarter valued at $36,000. Sanctuary Advisors LLC bought a new stake in Kodiak Sciences in the second quarter worth $36,000. LJI Wealth Management LLC boosted its holdings in Kodiak Sciences by 21.3% in the third quarter. LJI Wealth Management LLC now owns 17,100 shares of the company's stock worth $45,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Kodiak Sciences during the second quarter worth $127,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Kodiak Sciences Company Profile
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Read More
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
